ReviewMolecular biology reports2026
Molecular mechanisms, functional diversity, and therapeutic implications of HSP90 isoforms in lung cancer.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heat shock protein 90 (HSP90) is a critical molecular chaperone that ensures the stability and maturation of oncogenic client proteins in lung cancer. This review examines the distinct roles of HSP90α, HSP90β, GRP94 and the mitochondrial paralog TRAP1 in driving disease progression. While HSP90α governs invasiveness and metastasis, HSP90β maintains homeostatic oncogenic signalling. TRAP1 serves as a metabolic lynchpin, facilitating metabolic reprogramming, mitochondrial cytoprotection, and resistance to apoptosis. Together, these isoforms stabilize key drivers such as EGFR, ALK and KRAS, fostering therapeutic resistance. Utilizing systems biology, bioinformatics and comparative analysis of experimental studies, this review explores the high-throughput identification of HSP90 isoforms as central "hub genes" within the lung cancer interactome. The therapeutic potential of mitochondrial-targeted drug delivery systems and isoform-selective inhibitors designed to minimize systemic toxicity are explored in detail. Ultimately, understanding isoform-specific dynamics and multi-omics regulatory networks is essential for developing personalized, selective interventions to overcome drug resistance and improve lung cancer management.
Indexed as
Identifiers
42955475What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.